valve

The most read articles in interventional cardiology

Interventional cardiology: the most read articles of 2022 in solaci.org

Discover the most read scientific articles on interventional cardiology of 2022 in our website. The FDA Approves Intravascular Lithotripsy for Calcified Lesions The&nbsp;US&nbsp;Food and Drug Administration&nbsp;(FDA)&nbsp;has cleared the shockwave lithotripsy system to treat severely calcified plaque lesions. Is Epinephrine Superior to Adenosine in No-REFLOW? In patients with&nbsp;acute coronary syndrome,&nbsp;no-reflow&nbsp;prevalence is&nbsp;32%. Different drugs—such as adenosine, verapamil,<a href="https://solaci.org/en/2023/01/05/interventional-cardiology-the-most-read-articles-of-2022-in-solaci-org/" title="Read more" >...</a>

Buen desempeño de la Sapien 3 en “trabajos” para los que no está diseñada

Real-World Results of Different Devices for TAVR

Transcatheter aortic valve replacement (TAVR) keeps growing in terms of the development of new devices, more extensive operator experience, and enhanced procedure planning. Nowadays, there are multiple device options, which depend on patient characteristics and operator experience. Two-arm studies compared these devices, analyzing the potential benefits of a certain valve over the others. This multicenter<a href="https://solaci.org/en/2023/01/04/real-world-results-of-different-devices-for-tavr/" title="Read more" >...</a>

Anillos aórticos pequeños, ¿Qué válvula deberíamos elegir?

Clinical Implications of the Presence of HALT in TAVR Patients: 5-Year Follow-Up

The duration of percutaneous aortic valve implants can be increasingly observed over time, regardless of their corresponding surgical risk. In the follow-up of different registries, the presence of subclinical valvular thrombosis, evidenced in tomographic studies as an increase in valvular thickness with hypoattenuation (a term known as HALT), was observed from protocolized images.&nbsp; This subclinical<a href="https://solaci.org/en/2023/01/03/clinical-implications-of-the-presence-of-halt-in-tavr-patients-5-year-follow-up/" title="Read more" >...</a>

La reparación de la válvula mitral con Mitraclip es segura en pacientes de alto riesgo

Is the PASCAL Device Effective against MitraClip?

Mitral regurgitation (MR) is the most common valvulopathy and full medical treatment at maximal tolerated doses has been shown quite effective to treat it. However, its limited in a group of patients that require valve intervention.&nbsp; At present, the ideal treatment is surgical valve replacement, which is in many cases is not viable because of<a href="https://solaci.org/en/2022/12/30/is-the-pascal-device-effective-against-mitraclip/" title="Read more" >...</a>

perforación coronaria en angioplastia

We Should Treat Significant Stable CAD in Patients Undergoing TAVR

Aortic stenosis is associated to significant coronary artery disease (CAD) in nearly 50% of cases.&nbsp; When we decide to treat aortic disease using surgery, it has been established we should also treat heart disease.&nbsp; However, when using transcatheter aortic valve replacement (TAVR), this is still unclear, given that in many occasions we see stable lesions<a href="https://solaci.org/en/2022/12/30/we-should-treat-significant-stable-cad-in-patients-undergoing-tavr/" title="Read more" >...</a>

Aspirina o clopidogrel post TAVI: Guías y estudios llenos de contradicciones

Is Clopidogrel Monotherapy Safe After a Month of Dual Antiplatelet Therapy in Diabetic Patients?

Currently, many randomized studies have suggested that short-term dual antiplatelet therapy (DAPT) followed by monotherapy reduces bleeding without increasing major cardiovascular events after percutaneous coronary intervention (PCI). A meta-analysis of six randomized studies has shown this benefit using ticagrelor monotherapy after short DAPT. However, there is no data on the results of clopidogrel monotherapy. Researchers<a href="https://solaci.org/en/2022/12/27/is-clopidogrel-monotherapy-safe-after-a-month-of-dual-antiplatelet-therapy-in-diabetic-patients/" title="Read more" >...</a>

How Do We Manage Antiaggregation in BARC I Bleeding after AMI?

Dual antiplatelet therapy (DAPT) after acute myocardial infarction (AMI) has been shown useful to reduce thrombotic events, but one of its downsides is bleeding, especially in elderly patients. BARC bleeding type I, also called nuisance bleeding (NB), is of low frequency, but its evolution and impact remain unclear, as does its management.&nbsp; A subanalysis of<a href="https://solaci.org/en/2022/12/07/how-do-we-manage-antiaggregation-in-barc-i-bleeding-after-ami/" title="Read more" >...</a>

Mitral Trial: 2-Year Followup

At present, an important group of patients with mitral valve disease are at high surgical risk, especially those with deteriorated bio-prosthesis, severe mitral annulus calcification or those who had received mitral annuloplasty. Percutaneous treatment with balloon expandable valves is a valid option to treat these patients, seeing as their 30 day and one-year outcomes look<a href="https://solaci.org/en/2022/12/07/mitral-trial-2-year-followup/" title="Read more" >...</a>

El ticagrelor muestra beneficios en la función microvascular coronaria luego de un IAMSEST

P2Y12 Inhibitor Monotherapy vs Aspirin: Results of a Network Meta-Analysis

Revascularization and antiaggregation guidelines have typically recommended aspirin (AAS) as first choice for secondary prevention of cardiovascular events after DES stenting. However, these past few years this strategy has been called into question, seeing as studies have shown the superiority of P2Y12 inhibitor monotherapy (IP2Y12) with clopidogrel or ticagrelor. There is little data comparing both<a href="https://solaci.org/en/2022/12/05/p2y12-inhibitor-monotherapy-vs-aspirin-results-of-a-network-meta-analysis/" title="Read more" >...</a>

Resultados alentadores en la válvula mitral percutánea en los pacientes complejos

Severe Mitral Regurgitation and Cardiogenic Shock: Is Edge-to-Edge a Valid Strategy?

At present, cardiogenic shock continues to present high mortality despite the new treatments and ventricular assistance devices available in some centers.&nbsp; In this group, the presence of severe mitral regurgitation (MR) is around 5% and, on many occasions, it cannot be treated with surgery because of hemodynamic conditions.&nbsp; Edge-to-edge repair has been looked at by<a href="https://solaci.org/en/2022/11/30/severe-mitral-regurgitation-and-cardiogenic-shock-is-edge-to-edge-a-valid-strategy/" title="Read more" >...</a>

Top